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1. Introduction 
1.1 Overview of Drug Metabolizing Enzymes (DMEs) and transporters 
Drug metabolism can either lead to detoxification, bio-inactivation and/or elimination of 
the drug from the body. Metabolism can be broadly categorized into phases I and II. Phase I 
drug metabolizing enzymes (DMEs) primarily comprise of the Cytochrome (CYP) 450 
family of enzymes. CYP3A4 is the most common isoform expressed in human liver and 
intestine accounting for ~30-60% of CYPs (Nebert & Russell, 2002) More than 50% of the 
currently marketed drugs are metabolized by CYP3A4 in humans (Guengerich, 1999). Phase 
II metabolism consists of conjugation reactions forming polar metabolites leading to 
enhanced excretion. Phase II reactions include glucuronidation (Uridine 5'-diphospho-
glucuronosyltransferase, UGT) sulfation (Sulfotransferase, SULT), methylation 
(Methyltransferase), glutathione conjugation (Glutathione S-transferase, GST), etc. (Jancova 
et al., 2010; Meyer, 1996).   
Drug transporters play a central role in the absorption, distribution, metabolism and 
elimination (ADME) processes of xenobiotics across the cellular barriers. They are broadly 
classified into uptake and efflux transporters which facilitate drug disposition in or out of 
the cells (Mizuno et al., 2003). Major transporters include, but are not limited to: multidrug 
resistant gene/P-glycoprotein (MDR/P-gp), multidrug resistance associated protein (MRP1-
3), breast cancer resistance protein (BCRP), organic anion transporting peptides (OATPs) 
and organic cationic transporters (OCTs) (Mizuno et al., 2003; Mizuno & Sugiyama, 2002).  
1.2 Altered drug metabolism and transport in pathophysiological conditions  
Several studies have shown that drug metabolism and transport is disrupted during 
diseases and altered pathophysiological conditions primarily due to reductions in gene 
expression of these enzymes and transporters (Aitken et al., 2006; Kato, 1977). The 
transcription factors such as nuclear factor-κB (NF-κB), CAAT enhancer-binding protein 
(C/EBP) or nuclear transcription factor E2-related factor 2 (Nrf2) have been shown to 
regulate DME and transporter gene expression in vivo and in vitro (Gonzalez & Lee, 1996; 
Shen & Kong, 2009; Zordoky & El-Kadi, 2009). In addition to basal transcription factors, the 
xenobiotic nuclear receptors, pregnane X receptor (PXR), constitutive androstane receptor 
(CAR) heterodimerize  with  the central nuclear receptor, retinoid X receptor (RXR) ǂ to 
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regulate the expression of DME and transporter genes (Chen et al., 2004; Goodwin et al., 
2002; Kast et al., 2002; Xie, 2008). Furthermore, nuclear receptors such as peroxisome 
proliferator activated  receptor (PPAR), liver X receptor (LXR) or farsenoid X receptor (FXR) 
can also regulate DME and transporter gene expression (Xie, 2008). The orphan nuclear 
receptor, hepatocyte nuclear factor (HNF) 4ǂ can regulate the gene expression of PXR and 
CAR mediated xenobiotic induction of CYP3A4 (Tirona et al., 2003).  
Altered drug metabolism can lead to adverse drug reactions which account for ~10% of 
hospitalized cases (Deng et al., 2009; Maddox et al., 2010). However, due to underreporting, 
the actual incidences may be much higher (Lazarou et al., 1998., Pirmohamed et al., 2004). As 
early as 1960s, variations in drug metabolism were observed in patients or animals with 
diabetes (Dixon et al., 1961), cancer (Kato et al., 1963), hepatitis (Klotz et al., 1974; McHorse et 
al., 1974) or influenza (Kraemer et al., 1982). Changes in drug metabolism were also 
associated with a corresponding change in the pharmacodynamics (PD) of drugs (Dixon et 
al., 1961; Kato et al., 1968). These early studies prompted the researchers to study the 
alterations in DME and transporter gene expression and activity in pathophysiological 
conditions such as cancer, diabetes/obesity, rheumatoid arthritis (RA), non-alcoholic fatty 
liver disease (NAFLD) and cardiovascular diseases (CVDs) such as hypertension, heart 
failure, or stroke, etc. (Alkayed et al., 2002; Charles et al., 2006; Fisher et al., 2008; 2009a; 
2009b; Thum & Borlak, 2002). Overall, the readers of this chapter will benefit from the 
discussions of the changes in expression of DMEs and transporters, and 
pharmacokinetics/pharmacodynamics (PK/PD) of clinically relevant medications in 
different pathophysiological conditions.  
2. Infection and inflammation 
2.1 Bacterial infections 
2.1.1 Drug metabolizing enzymes 
Most of the studies on regulation on DMEs have been documented with gram-negative 
bacteria. Of clinical relevance, sepsis induced by cecal ligation and puncture (CLP) is the 
most frequently used model owing to its close resemblance in the progression and 
characteristics of human sepsis (Wichterman et al., 1980). In a CLP rat model, total hepatic 
microsomal CYP content and activities were significantly reduced (Godellas et al., 1995). 
Infection of pigs with the gram-negative respiratory pathogen, Actinobacillus 
pleuropneumoniae, led to decreased clearances of antipyrine, caffeine, and acetaminophen 24 
h after inoculation. This was further supported by decreased microsomal metabolism of 
several CYP-dependent substrates (Monshouwer et al., 1995). Another widely studied gram-
negative pathogen, Citrobacter rodentium, is a natural murine pathogen which produces 
similar colonic pathology on the intestinal cells of the host as seen after enteropathogenic 
Escherichia coli infections in humans (Higgins et al., 1999). The mRNA and protein levels of 
CYP4F18 and 2D9 were induced in a live mouse model of inflammatory bowel disease 
induced by C. rodentium (Chaluvadi et al., 2009). The rapid down-regulation of CYP2Cs and 
CYP3As after intraperitoneal (i.p) injection and CYP4As after oral injection of C. rodentium 
were quantitatively and qualitatively different, suggesting that the effects of oral infection 
are not due to bacterial translocation to the liver (Chaluvadi et al., 2009).  
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Although, gram-positive infections account for more than 50% of the total community 
acquired infections (Martin et al., 2003), very few studies have linked the effects of gram-
positive bacteria on regulation of DMEs. It was shown that in patients suffering from gram-
positive bacteremia such as Pseudomonas or Staphylococcus infections, an increase in volume 
of distribution (Vd) and dilution of antimicrobial agents in plasma and extracellular fluids 
may occur, which needs careful monitoring of the dosage regimen (Pinder et al., 2002). 
Listeriosis, caused by Listeria monocytogenes, is one of the most critical food-borne diseases in 
humans. L. monocytogenes induced CNS infection in rodents significantly down-regulated 
mRNA, protein and activity of hepatic CYPs (Garcia Del Busto Cano & Renton, 2003).  
The gram-negative bacterial component, lipopolysaccharide (LPS), and the gram-positive 
bacterial component, lipoteichoic acid (LTA), serve as sterile infection models by inducing 
inflammatory responses in animals (Ginsburg, 2002; Leemans et al., 2002). LPS can down-
regulate the expression and activity of key hepatic, intestinal and renal DMEs in several 
animal species such as mice, rats or rabbits (Ghose et al., 2008; Sewer et al., 1996). 
Interestingly, studies have that changes in CYP expression and activity is dependent on the 
route of administrate at same dose of LPS (Shimamoto et al., 1998). We recently showed that 
LTA significantly down-regulated the gene expression of several phase I and phase II DMEs 
in mice (Ghose et al., 2009).  
2.1.2 Drug transporters  
Changes in expression of drug transporters can have significant impact on the safety and 
efficacy of the drugs. LPS treatment of mice significantly down-regulated P-gp and Mrp2, 
major transporters involved in disposition of clinically relevant drugs such as colchicine, 
verapamil, daunorubicin, cyclosporin A and the abundant food-derived carcinogen 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) (Dietrich et al., 2001; Petrovic et al., 
2007). LPS-treated mice had significantly lower hepatic P-gp (30% of control) and increased 
P-gp expression in the kidney (140% controls) (Hartmann et al., 2001; 2005).  
2.1.3 PK/PD studies 
As early as 1980’s, it was shown that vaccination with the bacillus Calmette-Guerin (BCG) 
decreased clearance of theophylline in human volunteers (Gray et al., 1983). Altered PK was 
observed in other bacterial infections induced by Streptococcus pneumoniae (decreased 
antipyrine clearance) or Mycoplasma pulmonis (increased Tilmicosin plasma levels) (Modric et 
al., 1998; Sonne et al., 1985). LPS injections in animals and humans altered PK parameters 
such as maximum plasma concentration (Cmax, increase), area under the curve (AUC, 
increase), half-life (T1/2), Vd and clearance (CL, decrease) of several widely prescribed 
medications such as cisplatin, antipyrine, theophylline, hexobarbital, gentamicin and 
vancomycin (Gous et al., 1995; Hasegawa et al., 1994; Ishikawa et al., 1990; Shedlofsky et al., 
1994). PK changes of drugs during bacterial infection or inflammation can profoundly affect 
the PD as well. E.g. turpentine oil-injected mice had very high anti-tumor activity of 
gimatecan compared to the controls (Frapolli et al., 2010). On the other hand, several studies 
have shown that inflammation does not affect the PD of drugs. E.g. despite of very high 
plasma concentrations of the calcium channel blocker, verapmil, or potassium channel 
antagonists, sotalol or propranolol; no change in the PD was seen in inflamed animals 
(Guirguis & Jamali, 2003; Kulmatycki et al., 2001; Mayo et al., 2000). The authors concluded 
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this to be due to altered receptor-functioning or receptor-ligand binding exhibited by 
inflammation. Nevertheless, the above studies need further evaluations to delineate the 
disparities in altered drug metabolism caused by different bacterial infections or 
inflammation which has significant clinical implications for drug therapy in disease states. 
2.2 Viral infections 
2.2.1 Drug metabolizing enzymes 
Viral infections can also stimulate the immune system releasing various inflammatory 
mediators from the immune cells (Mannering & Deloria, 1986). A survey of the literature 
reveals numerous studies on the effect of viral infections such as mouse-adapted influenza 
virus (Corbett & Nettesheim, 1973), Newcastle disease virus (Singh & Renton, 1981), 
encephalomyocarditis virus (Renton, 1981), chronic active hepatitis and cirrhosis (Schoene et 
al., 1972; Wilkinson, 1997) and HIV infection (Lee et al., 1993) on alteration of gene 
expression and activity of DMEs and oxidative pathways in animals and humans. Decreased 
levels of hepatic CYP1A2 were detected in children suffering from upper respiratory tract 
viral infections during an influenza outbreak (Chang et al., 1978; Kraemer et al., 1982). With 
exceptions of CYP2D6 mRNA and CYP1A2 activity, other major CYPs such as CYP2C9, 
2C19, and 3A4 in HCV-infected PXB mice (chimeric mouse with human hepatocytes) were 
comparable to the non-infected controls (Kikuchi et al., 2010). Recombinant adenovirus 
injections in Sprague-Dawley rats led to significant down-regulation of renal CYP2E1 and 
hepatic CYP3A2 and CYP2C11 expression and activity, and induction of CYP4A protein 
expression (Callahan et al., 2005; Le et al., 2006).  
2.2.2 Drug transporters 
A recent study showed that HIV-type 1 viral envelope glycoprotein gp120 decreased P-gp 
and Mrp expression levels in rat astrocytes (Ronaldson & Bendayan, 2006). However, due to 
the fact that HIV infected patients are on highly active antiretroviral therapy (HAART) 
consisting of numerous drugs, both, induction and suppression of drug transporters in HIV 
infection are reported (Giraud et al., 2010). Polyinosinic/polycytidylic acid [poly (I:C)] is 
widely used as a model of in vivo viral-induced inflammation. Poly (I:C) can induce 
interferons (IFNs) and pro-inflammatory cytokines such as interleukin (IL)-6, IL-10, IL-12, 
and tumor necrosis factor (TNF)-ǂ. A significant down-regulation of key maternal hepatic 
and placental drug transporters and their endogenous substrates was observed upon i.p 
injection of poly (I:C) in pregnant rats (Petrovic & Piquette-Miller, 2010) However, Abcb1b 
(ATP-binding cassette sub-family B member 1) and Abcc3 (ATP-binding cassette sub-family 
C) were significantly induced. A recent study in PXB mice infected with hepatitis C virus 
(HCV) reported significantly higher expression of MRP4 and OATP2B1 and lower 
expression of OCT1 compared to non-infected mice (Kikuchi et al., 2010).   
2.2.3 PK/PD studies 
During the 1982 influenza B outbreak in King County, Washington, 11 children whose 
asthma had previously been controlled with a stable theophylline dose, developed 
theophylline toxicity on this same dose (Kraemer et al., 1982). These children had a 
significant decrease in CL and increase in T1/2 of theophylline. HIV infections could also 
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lead to altered PK of levofloxacin and fluconazole (Goodwin et al., 1994; Tett et al., 1995). 
End-stage liver disease, which is largely the result of HCV infection, now accounts for up to 
50% of deaths among persons with HIV-1 infection (Bica et al., 2001). A clinical study in 
HIV-HCV-coinfected patients showed significantly lower nelfinavir oral clearances in HIV+ 
and HCV+ patients with and without cirrhosis compared to HIV+ and HCV-negative 
patients (Regazzi et al., 2005). This presses the need for therapeutic drug monitoring in 
individualizing nelfinavir dosage in HIV-HCV-coinfected patients. In addition, an increase 
in AUC and Cmax of several anti-retrovirals are reported in HCV-infected patients with 
moderate liver impairment (Veronese et al., 2000; Wyles & Gerber, 2005). Other studies have 
also shown significantly higher AUC of docetaxel and reduced glomerular filtration rate, 
suggesting changes in renal CYP in rats injected with the recombinant adenovirus 
expressing ǃ-galactosidase (Le et al., 2006; Wonganan et al., 2009). On the contrary, 
significantly reduced Cmax and AUC of ceftiofur hydrochloride were observed in pigs 
infected with porcine reproductive and respiratory syndrome virus compared to the 
uninfected pigs (Tantituvanont et al., 2009).  
2.3 Mechanisms for altered drug metabolism in infections and inflammation 
Bacterial or viral infections lead to activation of Toll-like receptor (TLR) signaling pathway, 
which leads to the induction of pro-inflammatory cytokines, IL-1ǃ, IL-6 and TNF-ǂ in the 
immune cells. In the liver, TLRs are present on the cell surface of various immune cells (the 
resident macrophages or Kupffer cells) as well as the hepatocytes (Scott et al., 2009). Out of 
the 13 TLRs identified in mammals, TLR4 is activated by the gram-negative component, 
LPS, and TLR2 is activated by the gram-positive component, LTA (Aliprantis et al., 1999; 
Takeuchi et al., 1999). We and others have shown down-regulation of Cyp3a11 and P-gp in 
LPS sensitive TLR4 wild type (C3HeB/FeJ) mice could not be detected in TLR4-mutant 
(C3H/HeJ) mice (Ghose et al., 2008; Goralski et al., 2003; 2005). Recent data from our lab 
showed that down-regulation of gene expression of key hepatic phase I and phase II DMEs 
in TLR2+/+ mice by LTA was blocked in TLR2-/- mice (Ghose et al., 2009). We also observed 
that LTA down-regulated Mrp2, had no effect on Mrp3 and induced Mdr1b expression. 
Although, most of the studies have cited the role of Kupffer cell-derived TLRs in hepatic 
drug metabolism, we and others have also shown that LPS or LTA treatment of primary 
mouse hepatocytes can directly affect the DMEs via TLRs present on the hepatocytes, 
independent of cytokines (Ferrari et al., 2001; Ghose et al., 2011a). TLR-mediated signaling is 
initiated by the down-stream adaptor protein, Toll-interleukin 1 receptor domain containing 
adaptor protein (TIRAP) (Kagan & Medzhitov, 2006; O'Neill & Bowie, 2007). We showed 
that TIRAP was involved only in TLR2-mediated regulation of DME and transporter genes 
(Ghose et al., 2011a), and not by TLR4 (Ghose et al., 2008).  
Cytokines are involved in alteration of DMEs and transporters in vitro (Barker et al., 1992; 
Muntane-Relat et al., 1995). LPS-treatment of primary rat cocultures of hepatocytes and 
Kupffer cells significantly suppressed phenobarbital-mediated induction of CYP2B1 
(Milosevic et al., 1999). This decrease was associated with a 5-fold induction in TNF-ǂ 
released from the Kupffer cells in cocultures. In vitro studies with cytokine-treated rat or 
human hepatocytes led to decreased expression and activity of several drug transporters 
including efflux pumps such as P-gp,  MRP2, 3 and 4, and BCRP, sodium-taurocholate 
cotransporting polypeptide (NTCP), a major sinusoidal transporter handling bile acids, 
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uptake transporters such as OATP-B, OATP-C, and OATP-8 (Diao et al., 2010; Le Vee et al., 
2008; Lee & Piquette-Miller, 2003; Sukhai et al., 2000; Vee et al., 2009).  
However, recent evidence suggests cytokines may not be playing a major role in regulation 
of DMEs. Earlier studies in TNF-ǂ-/- and IL-6-/- knockout mice revealed that DMEs were still 
down-regulated (Warren et al., 1999; 2001). A recent study by Kinloch et al in 
TNFR1−/−, IL1R1−/− and Kupffer cell depleted mice showed that only TNF-ǂ, but not IL-1ǃ 
and Kupffer cells, was involved in regulation of CYP3A11 and 3A25 oral C. rodentium 
infection (Kinloch et al., 2011). In addition, we showed that although down-regulation of 
DMEs was blocked in LTA-treated TIRAP-/- mice, hepatic cytokine gene expression 
remained unchanged (Ghose et al., 2011a). 
Nitric oxide (NO), released from macrophages and hepatocytes during inflammation is also 
known to regulate DMEs (Morris & Billiar, 1994). However, contrasting results have been 
reported for the role of NO in regulation of DMEs in cytokine-treated primary rat 
hepatocytes (Carlson & Billings, 1996; Sewer & Morgan, 1997). IL-1ǃ and TNF-ǂ-mediated 
down-regulation of CYP protein was NO dependent, but not in IL-6 mediated down-
regulation (Carlson & Billings, 1996). NO was also shown to regulate the suppression of 
UGT activities in cytokine-treated hepatocytes (Monshouwer et al., 1996).  
Several studies have shown that inflammation-mediated activation of NF-κB plays a 
significant role in down-regulation of DMEs (Abdulla et al., 2005; Gilmore, 2006; Ke et al., 
2001). NF-κB can either indirectly regulate CYP gene expression through mutual 
repression between NF-κB and nuclear receptors, or can directly regulate CYP gene 
expression through binding to NF-κB response element in the promoter region of CYP 
genes (Pascussi et al., 2003). Interaction of NF-κB with nuclear receptors during 
pathophysiological conditions can alter expression of DMEs (Gu et al., 2006). 
Inflammation-mediated activation of mitogen activated protein kinase (MAPK), c-Jun-N-
terminal kinase (JNK), also regulates nuclear receptors and DMEs (Adam-Stitah et al., 
1999; Yu et al., 1999). Recent experiments in human gastric carcinoma and pancreatic 
carcinoma cell lines suggested a prominent role of JNK activation in down-regulation of 
P-gp protein expression (Zhou et al., 2006). However, further detailed studies using in 
vitro models such as cell lines or primary hepatocytes, and specific inhibitors of these cell 
signaling components will significantly contribute in understanding the mechanistic 
regulation of DMEs and transporters during inflammation.  
We speculate that down-regulation of nuclear receptors during inflammation might be 
involved in regulating the gene expression of DMEs and transporters in animal models 
(Ghose et al., 2004, 2008, 2009; Synold et al., 2001). We also showed that down-regulation of 
nuclear receptors by LPS in TLR4+/+ or by LTA in TLR2+/+ mice was blocked in TLR4 
mutant or TLR2-/- mice (Ghose et al., 2008, 2009, 2011a). On the contrary, mRNA and protein 
expression of several CYPs did not differ in PXR-/- or PPAR-/- mice treated with LPS 
(Richardson & Morgan, 2005). Similarly, it was shown that PXR was least important in 
regulating several efflux and uptake drug transporters using PXR wild type or PXR null mice 
treated with LPS (Teng & Piquette-Miller, 2005). However, the down-regulation of Bsep and 
Mrp2 mRNA in IL6-treated wild type mice was attenuated in the PXR null mice. Thus, 
involvement of nuclear receptors in inflammation-mediated regulation of DMEs and 
transporters may depend on the nature of the inflammatory stimuli.  
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3. Cancer 
3.1 Drug metabolizing enzymes 
Owing to the fact that, most anticancer drugs have a very low or narrow therapeutic index, 
alteration of DMEs can lead to life-threatening adverse drug reactions or increased risk of 
treatment failure in patients undergoing chemotherapy. Decreased hepatic microsomal 
DME activity was detected in tumor bearing rats with Walker carcinosarcoma 256, where 
impaired metabolism of hexobarbital, strychnine and meprobamate was observed (Kato et 
al., 1963). Due to difficulties in obtaining human liver tissue from cancer patients, an 
Engelbreth-Holm-Swarm (EHS) sarcoma mouse model bearing transgenic CYP3A4/lacZ 
gene was developed (Charles et al., 2006). Reduced hepatic levels of the transgene-derived ǃ-
galactosidase, as quantified by o-nitrophenyl-ǃ-D-galactopyranoside assay, and Cyp3a11 
mRNA and protein was observed in these mice (Charles et al., 2006). Tumors derived from 
the surface of the ovary account for the vast majority of ovarian tumors (approximately 
80%). Altered gene expression ratio of CYP3A4/ABCB1 (P-gp) in cancer cells grown from 
epithelial ovarian tumors had significant contribution in altering docetaxel disposition 
(DeLoia et al., 2008). On the other hand, there was no significant correlation in 
CYP2C8/ABCB1 ratio suggesting that paclitaxel disposition may require additional critical 
gene products. The expression of several phase II DMEs was also characterized in EHS 
tumor-bearing mice (Charles et al., 2006). Out of 8 GSTs studied, six were reduced and two 
unchanged; SULT1A1 was increased while SULT2A1 and UGT2B5 were reduced, and no 
change was observed in UGT1A7. Tamoxifen remains the first-line targeted treatment for 
the estrogen receptor ǂ-positive breast cancer patients and undergoes metabolism in the 
breast tissue which also consists of several DMEs (Williams & Phillips, 2000). In a study 
examining the role of methylation patterns of genes responsible for tamoxifen metabolism, 
higher methylation rate of N-acetyl transferase-1 (NAT1), a phase II DME gene, was 
observed in human breast cancer tissues compared to control breast tissues (Kim et al., 2010).  
3.2 Drug transporters 
Changes in the genetic variability in clinical specimens as well as over expression of ABC 
transporter family in tumors have been shown to play a critical role in multidrug resistance 
to several anticancer drugs (Hoffmeyer et al., 2000; Robinson et al., 1997; Yoh et al., 2004; 
Young et al., 1999). A recent study showed significant reductions in the mRNA levels 
of Mdr2, Mrp2, Mrp3, Ntcp, Oatp 2, bile salt export pump (Bsep), Bcrp, whereas Mdr1a and 
Oatp1 remained unchanged (Sharma et al., 2008).  
3.3 PK/PD studies 
Cancer-induced changes in the PK and PD profiles of several drugs have been documented 
since the late 1960s (Kato et al., 1968; Rosso et al., 1968, 1971). In a clinical study, the 
absorption rate constant, apparent Vd and serum CL of penbutolol (antihypertensive drug) 
were significantly reduced in the cancer group (Aguirre et al., 1996). PD effect (reduction in 
heart rate) of penbutolol did not vary statistically in respect to baseline values in cancer 
patients (Aguirre et al., 1996). Reduction in the metabolism of omeprazole (CYP2C19 
substrate) has also been observed in patients with advanced cancer (Williams et al., 2000). 
Reduced CYP3A expression resulted in >2 fold increase in the sleep time in tumor bearing 
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mice receiving the widely used sedative-hypnotic, midazolam, (CYP3A specific substrate) 
(Charles et al., 2006). 
3.4 Mechanisms of cancer-mediated altered drug metabolism  
Since the 1800s, it was observed that chronic inflammation is frequently associated with the 
onset and progression of various cancers (Balkwill & Mantovani, 2001). A strong association 
between cancer progression and induction of cytokines or acute phase reactive proteins in 
tumors is documented (Burke & Balkwill, 1996; Burke et al., 1996; Naylor et al., 1993). E.g. 
EHS tumor-bearing mice had significantly higher circulating plasma levels of IL-6 (25 
pg/ml) compared to the control mice (below detection limit). IL-6 mediated activation of 
JNK was also evident in EHS tumor-bearing mice, which again prompts the important role 
of JNK in regulation of DMEs. Studies have shown that TLR expression is enhanced in 
tumor cells lines (Yu & Chen, 2008). However, the role of TLRs in alteration of DMEs and 
transporters in cancer has never been investigated. 
The role of NF-κB activation in acute inflammation has been suggested in carcinogenesis 
(Karin et al., 2002; Lind et al., 2001). Cancer-mediated alteration of DMEs and transporters 
may possibly be regulated by over-expression of NF-κB. A recent study highlighted the role 
of extra hepatic malignancies in down-regulation of PXR and CAR in tumor-bearing mice 
(Kacevska et al., 2011). This study prompts to link the reduction in nuclear receptors with 
altered drug metabolism in cancer. However, additional studies with nuclear receptor 
knockout animal models with tumors will help identify their direct role in regulation of 
DMEs and transporters. Overall, all these studies imply that tumor-mediated inflammation 
may play an integral role in drug response and toxicity of various anticancer agents.  
4. Diabetes and obesity 
4.1 Drug metabolizing enzymes 
Another prevalent pathophysiological condition affecting millions of people in the world is 
the occurrence of diabetes and obesity. As per the latest statistical report, 366 million people 
in the world will have diabetes by 2030 (Wild et al., 2004). Dixon et al demonstrated that 
alloxan-induced diabetes decreased hexobarbital, chlorpromazine, and codeine metabolism 
in male rats (Dixon et al., 1961, 1963). Although, streptozotocin-induced diabetes in rats and 
hamsters significantly induced hepatic and renal CYP2E1 and 4A2 protein levels (Chen et 
al., 1996; Shimojo et al., 1993), suggesting altered metabolism of ketones and fatty acids in 
diabetes, hepatic CYP2E1 protein levels remained unchanged in streptozotocin-induced 
diabetic mice livers (Chen et al., 1996; Sakuma et al., 2001). A recent study showed 
differential effects of alloxan-induced diabetes on protein expression and activity of CYP2E1 
(increased) and CYP2B4 (decreased) in rabbits (Arinc et al., 2005). Altered gene expression of 
DMEs in genetically obese zucker fatty rats (reduction in CYP2B1/2 and Mrp3) and db/db 
mice (increase in CYP2B10) are also reported (Xiong et al., 2002; Yoshinari et al., 2006a). 
Studies have reported interesting results on DME gene and protein expression for different 
diet-induced obese (DIO) animal models. E.g. Although Cyp3a11 gene and protein 
expression were significantly reduced in both long term (12 weeks) and short term 
treatment (1 week) of high fat diet (HFD), Cyp2c9 gene expression was significantly reduced 
only in the short term HFD treatment (Yoshinari et al., 2006b). We recently showed that 
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mRNA levels of the phase II DMEs (Ugt1a1, Sult1a1, Sultn) were reduced ~30-60% in mice 
fed high-fat diet (HFD, 60% kcal fat for 14 weeks) compared to low fat diet (LFD, 10% kcal 
fat) mice (Ghose et al., 2011b). RNA levels of Cyp2e1 and Cyp1a2 were unaltered in HFD 
mice. These findings indicate that regulation of CYPs is dependent on the model of diabetes 
and obesity, and is tissue, isoform and species-specific. 
4.2 Drug transporters 
Streptozotocin treatment in rats increased hepatic levels of Mdr2, leading to increased 
phospholipid secretion into bile (van Waarde et al., 2002). Another study also showed that 
the hepatic expression of uptake transporters (Oatp1a1, 1a4, 1b2, 1a6, 2b1, and Ntcp) in 
diabetic mice decreased significantly compared to the wild type controls (Cheng et al., 2008). 
Our recent study showed no effect of high fat in DIO mice on gene expression of hepatic 
transporters (Mrp2 and 3, and Mdr1b) (Ghose et al., 2011b). 
4.3 PK/PD studies 
Obesity-associated alterations in phase II metabolism were reported in 1980’s. E.g. 
clearances of oxazepam and lorazepam, widely used benzodiazepines and excreted as 
glucuronide conjugates, were significantly increased in obese patients (Abernethy et al., 
1983). Similarly, increased metabolism of chlorzoxazone (CYP2E1 substrate) to 6-
hydroxychlorzoxazone was observed in obese individuals. This was attributed to increased 
CYP2E1 activity associated with obesity (O'Shea et al., 1994). Animal studies performed 
using a diabetes mellitus rat model (induced by alloxan or streptozotocin treatment) have 
reported altered PK of drugs such as acetaminophen, chlorzoxazone, theophylline, 
clarithromycin, furosemide, and methotrexate (Baek et al., 2006; Kim et al., 2005a, 2005b; 
Park et al., 1996, 1998; Watkins & Sherman, 1992). Although, no changes in PD of atracurium 
were reported in obese animals compared to lean control (Varin et al., 1990), triazolam-
induced sedation in obese humans increased significantly compared to normal weight men 
(Derry et al., 1995). We also observed similar disparities in the PD of midazolam, CYP3A 
substrate, (increased sleep time) and zoxazolamine, CYP2E1 substrate (no change) in DIO 
mice (Ghose et al., 2011b). This can be attributed to decrease in CYP3A and no change in 
CYP2E1 expression. Thus, the differential effects of obesity on PD of drugs may depend on 
the DME, or the drug or the target organ itself.  
4.4 Mechanisms of altered drug metabolism in diabetes/obesity 
The major pathophysiological manifestation in diabetes/obesity is characterized by low-
level chronic and local inflammation, such as release or over expression of TNF-ǂ and C-
reactive protein in adipose tissue (Hotamisligil et al., 1993; Wellen & Hotamisligil, 2005). 
However, the role of inflammation in regulation of DMEs and transporters in 
diabetes/obesity remains unclear. Hormonal regulation of DMEs in diabetes/obesity has 
also been addressed before (Thummel & Schenkman, 1990). Although an increase in mRNA 
or protein levels of CYP2E1 have been observed in obese patients (Lucas et al., 1998), db/db 
mice showed no such effects (Yoshinari et al., 2006a). This can possibly be due to 
hyperinsulinemia leading to a faster turnover (shorter CYP2E1 mRNA half-life) by insulin 
(De Waziers et al., 1995). Various studies have shown that phosphatidylinositol-3-kinase 
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(PI3K) signaling, using PI3K inhibitors, wortmannin and LY294002, ameliorated insulin-
mediated decrease in CYP2E1 and phase II enzymes (ǂ-GST) mRNA (Kim et al., 2006; Kim & 
Novak, 2007; Woodcroft et al., 2002).  
Interestingly, lower expression of CAR and CYP2B in obese Zucker rats and ~2 fold 
induction in obese and genetically diabetic mice (db/db) on HFD (Xiong et al., 2002; Yoshinari 
et al., 2006b) were reported. This discrepancy in obese Zucker rats and db/db mice in 
regulating expression profiles of CYPs and nuclear receptors can be explained by the 
difference in the position of mutation of leptin receptor gene (Chua et al., 1996; Lee et al., 
1996). We recently showed that expression of PXR and CAR; and protein levels of RXRǂ 
were significantly reduced in HFD mice (Ghose et al., 2011b). Thus, a complex set of 
processes including but not limited to cytokines, nuclear receptors, insulin sensitization or 
downstream signaling molecules, may regulate DMEs and transporters in diabetes/obesity. 
5. Non-alcoholic fatty liver disease  
5.1 Drug metabolizing enzymes 
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent with an estimated world 
population between 14% and 24% being affected. NAFLD comprises of symptoms ranging 
from simple steatosis (fatty liver) to the more severe non-alcoholic steatohepatitis (NASH, 
fatty liver with infiltration of inflammatory cells) to progressive hepatic fibrosis and to 
cirrhosis (Reynaert et al., 2005). Alteration of hepatic CYP2E1 was first noted in humans with 
NASH (Weltman et al., 1998). Later studies have shown significant contribution of NAFLD 
(comprising of both, simple stage fatty liver as well as NASH) on expression and activity of 
DMEs in animals (Fisher et al., 2008, 2009a, 2009b). Similarly, in vitro studies in primary 
human or animal hepatocyte cell cultures from steatotic or non-steatotic livers showed a 
profound impact of steatosis on the metabolic functionality of hepatocytes (Donato et al., 
2007; Fisher et al., 2004; Gomez-Lechon et al., 2004). Significant reductions in CYP1A2, 2C9, 
2E1 and 3A4 activities in fat-overloaded hepatocytes were observed compared with 
control hepatocytes obtained from the same liver sample (Fisher et al., 2008).  
5.2 Drug transporters 
Decreased mRNA and protein expression of uptake transporters such as NTCP, OATP1a1, 
1a4, 1b2 and 2b1; and OAT 2 and 3 were observed in NAFLD (Fisher et al., 2009a).  
5.3 PK/PD studies 
Studies have shown interesting results with acetaminophen (APAP) PK in rats and humans 
with NAFLD. Children with NAFLD had significantly higher concentrations of APAP-
glucuronide (APAP-G) in serum and urine compared with controls, with no significant 
differences in PK of APAP among the 2 groups (Barshop et al., 2011). Another study showed 
that biliary concentrations of APAP-sulfate (APAP-S), APAP-G, and APAP-glutathione were 
reduced in MCD (methionine- and choline-deficient) rats (Lickteig et al., 2007a). However, 
plasma levels of APAP-G were also elevated in MCD rats, similar to that observed in children 
(Barshop et al., 2011). A clinical study evaluated the effect of NAFLD on PK of silymarin 
(Schrieber et al., 2008). The AUC0-24h for the sum of total silymarin flavonolignans was ~3-4 fold 
higher in patients with NAFLD (p<0.03), compared with healthy volunteers.  
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5.4 Mechanisms of altered drug metabolism in NAFLD 
Several mechanisms have been proposed for the effect of NAFLD on altered drug 
metabolism. Deposition of fat in human hepatocytes can lead to a marked impairment in 
CYP mRNA and activity (Donato et al., 2006). Fisher et al observed intense staining for IL-1ǃ 
in steatotic livers, indicating that experimental steatosis and NASH results in increased 
hepatocellular inflammation (Fisher et al., 2009a). Studies have shown ambiguous results on 
expression of nuclear receptors and transcription factors in NAFLD (Fisher et al., 2009b; 
Hardwick et al., 2010; Lickteig et al., 2007b). Except for PXR, which was significantly 
increased by 1.4 fold, the other nuclear receptors (AhR, CAR, PPARǂ and Nrf2) were not 
altered (Fisher et al., 2008). Therefore, various factors need to be taken into account for 
improved pharmacotherapy in patients with NAFLD.  
6. Cardiovascular disorders 
6.1 Drug metabolizing enzymes 
CYPs in humans are responsible for metabolizing a large number of cardiovascular 
medications, including ǃ-blockers, calcium channel blockers and angiotensin receptor 
antagonists (Abernethy & Flockhart, 2000). Alteration in DMEs could be of particular 
clinical relevance in patients with heart failure because these patients take more than 10 
medications on average. Although, not detected in the normal human heart, failing hearts 
expressed CYP11B1 and 11B2 (Young et al., 2001). Surprisingly, an up-regulation in CYP2J2, 
1B1, 2E1, 4A10 and 2F2 gene expression was reported in the failing heart (Tan et al., 2002). 
Increased cardiac CYP11B2 mRNA was associated with increased myocardial fibrosis and 
the severity of left ventricular dysfunction in patients with heart failure (Satoh et al., 2002). It 
was shown that the production of testosterone metabolites, including dihydrotestosterone 
and androstenedione, was significantly increased in hypertrophic human hearts (Thum & 
Borlak, 2002). Transient ischemic attacks (TIA) are risk factors for strokes.  A recent study 
showed that cerebral infarct size was reduced in TIA-preconditioned animals and CYP2C11 
mRNA and protein were coincidentally increased in the brain after experimentally induced 
TIA (Johnston, 2004). Genetic polymorphisms of DMEs are commonly associated with heart 
failure and hypertension (Kivisto et al., 2005). E.g. a study in Japanese subjects reported that 
CYP2C9 wild type carriers had lower systolic blood pressure after losartan (metabolizes to 
the active metabolite EXP3174) therapy than poor metabolizers (Sekino et al., 2003).  
6.2 Drug transporters 
A recent study demonstrated a selective disease-dependent regulation of the high-affinity 
carnitine transporter, OCTN2, in patients with dilated cardiomyopathy, whereas the other 
OCT(N)s were unaffected (Grube et al., 2011). 
6.3 PK/PD studies 
It was shown that lidocaine plasma clearance was significantly decreased in patients with 
cardiac failure and this was associated with decreased liver blood flow (Thomson et al., 
1971). Another group also observed reduced plasma clearance of lignocaine in patients 
suffering from myocardial infarction without cardiac failure (Prescott et al., 1976). Thus, the 
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mounting evidence for the effect of CVDs on DMEs and transporters needs to be extended 
for further PK/PD studies. 
6.4 Mechanisms of altered drug metabolism in CVDs 
Failing or hypertensive hearts are susceptible to infiltration by pro-inflammatory cytokines 
and reactive oxygen species induced by stress (Fliser et al., 2004). Studies have shown that 
increased circulating levels of TNF-ǂ and IL-6 in patients with congestive heart failure were 
inversely proportional to CYP2C19 and CYP1A2 activity (Frye et al., 2002). Similarly, down-
regulation of OCTN2 expression in patients with dilated cardiomyopathy inversely 
correlated with cardiac CD3+ T-cell count (Grube et al., 2011). In addition, cardiac cytokine 
release may affect OCTN2 expression during cardiomyopathy associated with 
inflammation.  
7. Rheumatoid Arthritis (RA) 
7.1 Drug metabolizing enzymes 
Rheumatic diseases are estimated to affect up to 1.1% of the world’s population (Harris, 
1980). Various studies have shown that gene expressions of DMEs are altered in adjuvant 
arthritis (AA) rats (Achira et al., 2002b, 2002c; Projean et al., 2005). Similarly, activities of 
CYP3A were significantly decreased in AA rats compared to control rats (Uno et al., 2007).  
7.2 Drug transporters 
Decreased activity of hepatic P-gp in the isolated perfused liver of AA rats was reported 
(Achira et al., 2002c; Uno et al., 2007). Decrease in P-gp activity corresponded with the 
decreased levels of Mdr1a mRNA and P-gp protein in AA rats.  
7.3 PK/PD studies 
PK/PD changes such as elevated plasma levels of acebutolol, cyclosporin A, propranolol 
and prolongation of sleep time with pentobarbital were observed in AA rats compared to 
normal rats (Dipasquale et al., 1974; Piquette-Miller & Jamali, 1992, 1993; Shibata et al., 1993). 
Based on these early observations, recent studies have also shown altered PK of 
methotrexate, T-5557 (novel anti-inflammatory agent) and doxorubicin in AA animals 
(Achira et al., 2002a, 2002b; 2002d). Although, a significant increase in the plasma 
concentrations of verapamil in rats and humans with underlying arthritis were reported, 
there were no changes in the PD of verapamil (prolongation of PR interval) (Mayo et al., 
2000; Sattari et al., 2003). This discrepancy was then attributed to a decrease in the receptor-
ligand affinity in inflammation (Laporte et al., 1998; Shore et al., 1997).  
7.4 Mechanisms of altered drug metabolism in RA 
AA animal models represent a systemic inflammatory disease with bone and cartilage 
changes similar to those observed in RA (Williams et al., 1992). Down-regulation of hepatic 
P-gp in AA rats was attributed to elevated levels of cytokines such as TNF-ǂ and IL-6 but 
not IL-1ǃ (Philippe et al., 1997). Similarly, increased plasma concentrations of drugs in AA 
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rats correlated with increased serum TNF-ǂ level (Sattari et al., 2003). Several in vitro and in 
vivo studies have shown up-regulation of NF-κB in RA and osteoarthritis (Handel et al., 
1995; Mor et al., 2005). It was recently demonstrated that PXR and CAR expression in small 
intestine was decreased in arthritis (Kawase et al., 2007b). In another study, bilirubin 
elimination was significantly decreased in collagen-induced arthritis (CIA) rats compared to 
normal rats (Kawase et al., 2007a), which was attributed to decreased expression of CAR in 
CIA rats. Thus, overall these studies imply that inflammatory pathways may be involved in 
the regulation of DMEs and transporters in arthritis.  
8. Conclusion 
A common theme of this chapter is that a multiplex of mechanisms are responsible for 
alterations of DMEs, transporters and PK/PD of drugs in different pathophysiological 
conditions. It is well-established that changes in gene expression of enzymes and 
transporters can lead to disruption in drug disposition in altered pathophysiological 
conditions including infection/inflammation, cancer, obesity, CVD, rheumatoid arthritis, 
etc. Studies show that induction of inflammatory mediators is an underlying factor common 
to all these pathophysiological conditions and may contribute to altered drug disposition in 
disease states. In addition, the generally accepted role of cytokines in alterations of DMEs 
and transporters needs further evaluation. We have established the involvement of Toll-like 
receptor signaling pathway in the regulation of DMEs and transporters, and our studies 
point to the role of cytokine-independent pathways in the liver. The role of transcription 
factors and nuclear receptors in the regulation of DMEs and transporters in disease states 
need further investigation. There is an urgent need to develop models for delineating the 
roles of individual inflammatory mediators or nuclear receptors in altered drug disposition 
in disease states. Understanding alterations of drug disposition in disease states is critical in 
predicting and preventing undesirable effects of clinically-relevant medications.  
9. References 
Abdulla, D.; Goralski, K. B.; Del Busto Cano, E. G. & Renton, K. W. (2005). The signal 
transduction pathways involved in hepatic cytochrome P450 regulation in the rat 
during a lipopolysaccharide-induced model of central nervous system 
inflammation. Drug Metab Dispos 33 1521-1531. 
Abernethy, D. R. & Flockhart, D. A. (2000). Molecular basis of cardiovascular drug 
metabolism: implications for predicting clinically important drug interactions. 
Circulation 101 1749-1753. 
Abernethy, D. R.; Greenblatt, D. J.; Divoll, M. & Shader, R. I. (1983). Enhanced glucuronide 
conjugation of drugs in obesity: studies of lorazepam, oxazepam, and 
acetaminophen. J Lab Clin Med 101 873-880. 
Achira, M.; Totsuka, R.; Fujimura, H. & Kume, T. (2002a). Decreased hepatobiliary transport 
of methotrexate in adjuvant arthritis rats. Xenobiotica 32 1151-1160. 
Achira, M.; Totsuka, R.; Fujimura, H. & Kume, T. (2002b). Tissue-specific regulation of 
expression and activity of P-glycoprotein in adjuvant arthritis rats. Eur J Pharm Sci 
16 29-36. 
Achira, M.; Totsuka, R. & Kume, T. (2002c). Decreased activity of hepatic P-glycoprotein in 
the isolated perfused liver of the adjuvant arthritis rat. Xenobiotica 32 963-973. 
www.intechopen.com
 
Topics on Drug Metabolism 
 
124 
Achira, M.; Totsuka, R. & Kume, T. (2002d). Differences in pharmacokinetics and 
hepatobiliary transport of a novel anti-inflammatory agent between normal and 
adjuvant arthritis rats. Xenobiotica 32 1139-1149. 
Adam-Stitah, S.; Penna, L.; Chambon, P. & Rochette-Egly, C. (1999). Hyperphosphorylation 
of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases. J Biol 
Chem 274 18932-18941. 
Aguirre, C.; Troconiz, I. F.; Valdivieso, A.; Jimenez, R. M.; Gonzalez, J. P.; Calvo, R. & 
Rodriguez-Sasiain, J. M. (1996). Pharmacokinetics and pharmacodynamics of 
penbutolol in healthy and cancer subjects: role of altered protein binding. Res 
Commun Mol Pathol Pharmacol 92 53-72. 
Aitken, A. E.; Richardson, T. A. & Morgan, E. T. (2006). Regulation of drug-metabolizing 
enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46 123-149. 
Aliprantis, A. O.; Yang, R. B.; Mark, M. R.; Suggett, S.; Devaux, B.; Radolf, J. D.; Klimpel, G. 
R.; Godowski, P. & Zychlinsky, A. (1999). Cell activation and apoptosis by bacterial 
lipoproteins through toll-like receptor-2. Science 285 736-739. 
Alkayed, N. J.; Goyagi, T.; Joh, H. D.; Klaus, J.; Harder, D. R.; Traystman, R. J. & Hurn, P. D. 
(2002). Neuroprotection and P450 2C11 upregulation after experimental transient 
ischemic attack. Stroke 33 1677-1684. 
Arinc, E.; Arslan, S. & Adali, O. (2005). Differential effects of diabetes on CYP2E1 and 
CYP2B4 proteins and associated drug metabolizing enzyme activities in rabbit 
liver. Arch Toxicol 79 427-433. 
Baek, H. W.; Bae, S. K.; Lee, M. G. & Sohn, Y. T. (2006). Pharmacokinetics of chlorzoxazone 
in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. J 
Pharm Sci 95 2452-2462. 
Balkwill, F. & Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 357 
539-545. 
Barker, C. W.; Fagan, J. B. & Pasco, D. S. (1992). Interleukin-1 beta suppresses the induction 
of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. J Biol Chem 267 8050-
8055. 
Barshop, N. J.; Capparelli, E. V.; Sirlin, C. B.; Schwimmer, J. B. & Lavine, J. E. (2011). 
Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. 
J Pediatr Gastroenterol Nutr 52 198-202. 
Bica, I.; McGovern, B.; Dhar, R.; Stone, D.; McGowan, K.; Scheib, R. & Snydman, D. R. (2001). 
Increasing mortality due to end-stage liver disease in patients with human 
immunodeficiency virus infection. Clin Infect Dis 32 492-497. 
Burke, F. & Balkwill, F. R. (1996). Cytokines in animal models of cancer. Biotherapy 8 229-241. 
Burke, F.; Relf, M.; Negus, R. & Balkwill, F. (1996). A cytokine profile of normal and 
malignant ovary. Cytokine 8 578-585. 
Callahan, S. M.; Ming, X.; Lu, S. K.; Brunner, L. J. & Croyle, M. A. (2005). Considerations for 
use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. J 
Pharmacol Exp Ther 312 492-501. 
Carlson, T. J. & Billings, R. E. (1996). Role of nitric oxide in the cytokine-mediated regulation 
of cytochrome P-450. Mol Pharmacol 49 796-801. 
Chaluvadi, M. R.; Kinloch, R. D.; Nyagode, B. A.; Richardson, T. A.; Raynor, M. J.; Sherman, 
M.; Antonovic, L.; Strobel, H. W.; Dillehay, D. L. & Morgan, E. T. (2009). Regulation 
of hepatic cytochrome P450 expression in mice with intestinal or systemic 
infections of citrobacter rodentium. Drug Metab Dispos 37 366-374. 
www.intechopen.com
 
Altered Drug Metabolism and Transport in Pathophysiological Conditions 
 
125 
Chang, K. C.; Bell, T. D.; Lauer, B. A. & Chai, H. (1978). Altered theophylline 
pharmacokinetics during acute respiratory viral illness. Lancet 1 1132-1133. 
Charles, K. A.; Rivory, L. P.; Brown, S. L.; Liddle, C.; Clarke, S. J. & Robertson, G. R. (2006). 
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of 
cancer. Clin Cancer Res 12 7492-7497. 
Chen, T. L.; Chen, S. H.; Tai, T. Y.; Chao, C. C.; Park, S. S.; Guengerich, F. P. & Ueng, T. H. 
(1996). Induction and suppression of renal and hepatic cytochrome P450-dependent 
monooxygenases by acute and chronic streptozotocin diabetes in hamsters. Arch 
Toxicol 70 202-208. 
Chen, Y.; Ferguson, S. S.; Negishi, M. & Goldstein, J. A. (2004). Induction of human CYP2C9 
by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X 
receptor. J Pharmacol Exp Ther 308 495-501. 
Cheng, Q.; Aleksunes, L. M.; Manautou, J. E.; Cherrington, N. J.; Scheffer, G. L.; Yamasaki, 
H. & Slitt, A. L. (2008). Drug-metabolizing enzyme and transporter expression in a 
mouse model of diabetes and obesity. Mol Pharm 5 77-91. 
Chua, S. C., Jr.; White, D. W.; Wu-Peng, X. S.; Liu, S. M.; Okada, N.; Kershaw, E. E.; Chung, 
W. K.; Power-Kehoe, L.; Chua, M.; Tartaglia, L. A. & Leibel, R. L. (1996). Phenotype 
of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 45 1141-
1143. 
Corbett, T. H. & Nettesheim, P. (1973). Effect of PR-8 viral respiratory infection of 
benz[a]pyrene hydroxylase activity in BALB/c mice. J Natl Cancer Inst 50 779-782. 
De Waziers, I.; Garlatti, M.; Bouguet, J.; Beaune, P. H. & Barouki, R. (1995). Insulin down-
regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in 
the rat hepatoma cell line. Mol Pharmacol 47 474-479. 
DeLoia, J. A.; Zamboni, W. C.; Jones, J. M.; Strychor, S.; Kelley, J. L. & Gallion, H. H. (2008). 
Expression and activity of taxane-metabolizing enzymes in ovarian tumors. Gynecol 
Oncol 108 355-360. 
Deng, X.; Luyendyk, J. P.; Ganey, P. E. & Roth, R. A. (2009). Inflammatory stress and 
idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 61 262-282. 
Derry, C. L.; Kroboth, P. D.; Pittenger, A. L.; Kroboth, F. J.; Corey, S. E. & Smith, R. B. (1995). 
Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses 
in obese and normal-weight men. J Clin Psychopharmacol 15 197-205. 
Diao, L.; Li, N.; Brayman, T. G.; Hotz, K. J. & Lai, Y. (2010). Regulation of MRP2/ABCC2 and 
BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes 
exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}. J Biol Chem 
285 31185-31192. 
Dietrich, C. G.; de Waart, D. R.; Ottenhoff, R.; Schoots, I. G. & Elferink, R. P. (2001). 
Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol Pharmacol 59 974-980. 
Dipasquale, G.; Welaj, P. & Rassaert, C. L. (1974). Prolonged pentobarbital sleeping time in 
adjuvant-induced polyarthritic rats. Res Commun Chem Pathol Pharmacol 9 253-264. 
Dixon, R. L.; Hart, L. G. & Fouts, J. R. (1961). The metabolism of drugs by liver microsomes 
from alloxan-diabetic rats. J Pharmacol Exp Ther 133 7-11. 
Dixon, R. L.; Hart, L. G.; Rogers, L. A. & Fouts, J. R. (1963). The Metabolism of Drugs by 
Liver Microsomes from Alloxan-Diabetic Rats: Long Term Diabetes. J Pharmacol 
Exp Ther 142 312-317. 
www.intechopen.com
 
Topics on Drug Metabolism 
 
126 
Donato, M. T.; Jimenez, N.; Serralta, A.; Mir, J.; Castell, J. V. & Gomez-Lechon, M. J. (2007). 
Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. 
Toxicol In Vitro 21 271-276. 
Donato, M. T.; Lahoz, A.; Jimenez, N.; Perez, G.; Serralta, A.; Mir, J.; Castell, J. V. & Gomez-
Lechon, M. J. (2006). Potential impact of steatosis on cytochrome P450 enzymes of 
human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 34 1556-1562. 
Ferrari, L.; Peng, N.; Halpert, J. R. & Morgan, E. T. (2001). Role of nitric oxide in down-
regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. 
Mol Pharmacol 60 209-216. 
Fisher, C. D.; Jackson, J. P.; Lickteig, A. J.; Augustine, L. M. & Cherrington, N. J. (2008). Drug 
metabolizing enzyme induction pathways in experimental non-alcoholic 
steatohepatitis. Arch Toxicol 82 959-964. 
Fisher, C. D.; Lickteig, A. J.; Augustine, L. M.; Oude Elferink, R. P.; Besselsen, D. G.; 
Erickson, R. P. & Cherrington, N. J. (2009a). Experimental non-alcoholic fatty liver 
disease results in decreased hepatic uptake transporter expression and function in 
rats. Eur J Pharmacol 613 119-127. 
Fisher, C. D.; Lickteig, A. J.; Augustine, L. M.; Ranger-Moore, J.; Jackson, J. P.; Ferguson, S. S. 
& Cherrington, N. J. (2009b). Hepatic cytochrome P450 enzyme alterations in 
humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab 
Dispos 37 2087-2094. 
Fisher, R. A.; Bu, D.; Thompson, M.; Wolfe, L. & Ritter, J. K. (2004). Optimization of 
conditions for clinical human hepatocyte infusion. Cell Transplant 13 677-689. 
Fliser, D.; Buchholz, K. & Haller, H. (2004). Antiinflammatory effects of angiotensin II 
subtype 1 receptor blockade in hypertensive patients with microinflammation. 
Circulation 110 1103-1107. 
Frapolli, R.; Zucchetti, M.; Sessa, C.; Marsoni, S.; Vigano, L.; Locatelli, A.; Rulli, E.; 
Compagnoni, A.; Bello, E.; Pisano, C.; Carminati, P. & D'Incalci, M. (2010). Clinical 
pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient 
variability is related to alpha1-acid glycoprotein plasma levels. Eur J Cancer 46 505-
516. 
Frye, R. F.; Schneider, V. M.; Frye, C. S. & Feldman, A. M. (2002). Plasma levels of TNF-
alpha and IL-6 are inversely related to cytochrome P450-dependent drug 
metabolism in patients with congestive heart failure. J Card Fail 8 315-319. 
Garcia Del Busto Cano, E. & Renton, K. W. (2003). Modulation of hepatic cytochrome P450 
during Listeria monocytogenes infection of the brain. J Pharm Sci 92 1860-1868. 
Ghose, R.; Guo, T. & Haque, N. (2009). Regulation of gene expression of hepatic drug 
metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, 
lipoteichoic acid. Arch Biochem Biophys 481 123-130. 
Ghose, R.; Guo, T.; Vallejo, J. G. & Gandhi, A. (2011a). Differential role of Toll-interleukin 1 
receptor domain-containing adaptor protein in Toll-like receptor 2-mediated 
regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. 
Drug Metab Dispos 39 874-881. 
Ghose, R.; Omoluabi, O.; Gandhi, A.; Shah, P.; Strohacker, K.; Carpenter, K. C.; McFarlin, B. 
& Guo, T. (2011b). Role of high-fat diet in regulation of gene expression of drug 
metabolizing enzymes and transporters. Life Sci 89 57-64. 
Ghose, R.; White, D.; Guo, T.; Vallejo, J. & Karpen, S. J. (2008). Regulation of hepatic drug-
metabolizing enzyme genes by Toll-like receptor 4 signaling is independent of Toll-
www.intechopen.com
 
Altered Drug Metabolism and Transport in Pathophysiological Conditions 
 
127 
interleukin 1 receptor domain-containing adaptor protein. Drug Metab Dispos 36 95-
101. 
Ghose, R.; Zimmerman, T. L.; Thevananther, S. & Karpen, S. J. (2004). Endotoxin leads to 
rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for 
reduced hepatic gene expression in inflammation. Nucl Recept 2 4. 
Gilmore, T. D. (2006). Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 
25 6680-6684. 
Ginsburg, I. (2002). Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2 
171-179. 
Giraud, C.; Manceau, S.; Decleves, X.; Goffinet, F.; Morini, J. P.; Chappuy, H.; Batteux, F.; 
Chouzenoux, S.; Yousif, S.; Scherrmann, J. M.; Blanche, S. & Treluyer, J. M. (2010). 
Influence of development, HIV infection, and antiretroviral therapies on the gene 
expression profiles of ABC transporters in human lymphocytes. J Clin Pharmacol 50 
226-230. 
Godellas, C. V.; Williams, J. F. & Fabri, P. J. (1995). Mixed-function oxidase activity in sepsis. 
J Surg Res 59 783-786. 
Gomez-Lechon, M. J.; Donato, M. T.; Castell, J. V. & Jover, R. (2004). Human hepatocytes in 
primary culture: the choice to investigate drug metabolism in man. Curr Drug 
Metab 5 443-462. 
Gonzalez, F. J. & Lee, Y. H. (1996). Constitutive expression of hepatic cytochrome P450 
genes. Faseb J 10 1112-1117. 
Goodwin, B.; Hodgson, E.; D'Costa, D. J.; Robertson, G. R. & Liddle, C. (2002). 
Transcriptional regulation of the human CYP3A4 gene by the constitutive 
androstane receptor. Mol Pharmacol 62 359-365. 
Goodwin, S. D.; Gallis, H. A.; Chow, A. T.; Wong, F. A.; Flor, S. C. & Bartlett, J. A. (1994). 
Pharmacokinetics and safety of levofloxacin in patients with human 
immunodeficiency virus infection. Antimicrob Agents Chemother 38 799-804. 
Goralski, K. B.; Abdulla, D.; Sinal, C. J.; Arsenault, A. & Renton, K. W. (2005). Toll-like 
receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse model of LPS-
induced CNS inflammation. Am J Physiol Gastrointest Liver Physiol 289 G434-443. 
Goralski, K. B.; Hartmann, G.; Piquette-Miller, M. & Renton, K. W. (2003). Downregulation 
of mdr1a expression in the brain and liver during CNS inflammation alters the in 
vivo disposition of digoxin. Br J Pharmacol 139 35-48. 
Gous, A. G.; Dance, M. D.; Lipman, J.; Luyt, D. K.; Mathivha, R. & Scribante, J. (1995). 
Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive 
Care 23 678-682. 
Gray, J. D.; Renton, K. W. & Hung, O. R. (1983). Depression of theophylline elimination 
following BCG vaccination. Br J Clin Pharmacol 16 735-737. 
Grube, M.; Ameling, S.; Noutsias, M.; Kock, K.; Triebel, I.; Bonitz, K.; Meissner, K.; 
Jedlitschky, G.; Herda, L. R.; Reinthaler, M.; Rohde, M.; Hoffmann, W.; Kuhl, U.; 
Schultheiss, H. P.; Volker, U.; Felix, S. B.; Klingel, K.; Kandolf, R. & Kroemer, H. K. 
(2011). Selective regulation of cardiac organic cation transporter novel type 2 
(OCTN2) in dilated cardiomyopathy. Am J Pathol 178 2547-2559. 
Gu, X.; Ke, S.; Liu, D.; Sheng, T.; Thomas, P. E.; Rabson, A. B.; Gallo, M. A.; Xie, W. & Tian, 
Y. (2006). Role of NF-kappaB in regulation of PXR-mediated gene expression: a 
mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory 
agents. J Biol Chem 281 17882-17889. 
www.intechopen.com
 
Topics on Drug Metabolism 
 
128 
Guengerich, F. P. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. 
Annu Rev Pharmacol Toxicol 39 1-17. 
Guirguis, M. S. & Jamali, F. (2003). Disease-drug interaction: Reduced response to 
propranolol despite increased concentration in the rat with inflammation. J Pharm 
Sci 92 1077-1084. 
Handel, M. L.; McMorrow, L. B. & Gravallese, E. M. (1995). Nuclear factor-kappa B in 
rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 38 1762-1770. 
Hardwick, R. N.; Fisher, C. D.; Canet, M. J.; Lake, A. D. & Cherrington, N. J. (2010). Diversity 
in antioxidant response enzymes in progressive stages of human nonalcoholic fatty 
liver disease. Drug Metab Dispos 38 2293-2301. 
Harris, M. (1980). Careers in nursing: caring for children with rheumatoid arthritis. Nursing 
(Lond) 880-881. 
Hartmann, G.; Kim, H. & Piquette-Miller, M. (2001). Regulation of the hepatic multidrug 
resistance gene expression by endotoxin and inflammatory cytokines in mice. Int 
Immunopharmacol 1 189-199. 
Hartmann, G.; Vassileva, V. & Piquette-Miller, M. (2005). Impact of endotoxin-induced 
changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug 
Metab Dispos 33 820-828. 
Hasegawa, T.; Nadai, M.; Wang, L.; Haghgoo, S.; Nabeshima, T. & Kato, N. (1994). Influence 
of endotoxin and lipid A on the renal handling and accumulation of gentamicin in 
rats. Biol Pharm Bull 17 1651-1655. 
Higgins, L. M.; Frankel, G.; Douce, G.; Dougan, G. & MacDonald, T. T. (1999). Citrobacter 
rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions 
similar to those in murine inflammatory bowel disease. Infect Immun 67 3031-3039. 
Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, 
I.; Gerloff, T.; Roots, I.; Eichelbaum, M. & Brinkmann, U. (2000). Functional 
polymorphisms of the human multidrug-resistance gene: multiple sequence 
variations and correlation of one allele with P-glycoprotein expression and activity 
in vivo. Proc Natl Acad Sci U S A 97 3473-3478. 
Hotamisligil, G. S.; Shargill, N. S. & Spiegelman, B. M. (1993). Adipose expression of tumor 
necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 87-
91. 
Ishikawa, M.; Ohzeki, R.; Takayanagi, Y. & Sasaki, K. (1990). Potentiation of cisplatin 
lethality by bacterial lipopolysaccharide pretreatment in mice. Res Commun Chem 
Pathol Pharmacol 70 375-378. 
Jancova, P.; Anzenbacher, P. & Anzenbacherova, E. (2010). Phase II drug metabolizing 
enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154 103-116. 
Johnston, S. C. (2004). Ischemic preconditioning from transient ischemic attacks? Data from 
the Northern California TIA Study. Stroke 35 2680-2682. 
Kacevska, M.; Downes, M. R.; Sharma, R.; Evans, R. M.; Clarke, S. J.; Liddle, C. & Robertson, 
G. R. (2011). Extrahepatic cancer suppresses nuclear receptor-regulated drug 
metabolism. Clin Cancer Res 17 3170-3180. 
Kagan, J. C. & Medzhitov, R. (2006). Phosphoinositide-mediated adaptor recruitment 
controls Toll-like receptor signaling. Cell 125 943-955. 
Karin, M.; Cao, Y.; Greten, F. R. & Li, Z. W. (2002). NF-kappaB in cancer: from innocent 
bystander to major culprit. Nat Rev Cancer 2 301-310. 
www.intechopen.com
 
Altered Drug Metabolism and Transport in Pathophysiological Conditions 
 
129 
Kast, H. R.; Goodwin, B.; Tarr, P. T.; Jones, S. A.; Anisfeld, A. M.; Stoltz, C. M.; Tontonoz, P.; 
Kliewer, S.; Willson, T. M. & Edwards, P. A. (2002). Regulation of multidrug 
resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X 
receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol 
Chem 277 2908-2915. 
Kato, R. (1977). Drug metabolism under pathological and abnormal physiological states in 
animals and man. Xenobiotica 7 25-92. 
Kato, R.; Frontino, G. & Vassanellip (1963). Decreased activities of liver microsomal drug-
metabolizing enzymes in the rats bearing Walker carcinosarcoma. Experientia 19 31-
32. 
Kato, R.; Takanaka, A. & Oshima, T. (1968). Drug metabolism in tumor-bearing rats. II. In 
vivo metabolisms and effects of drugs in tumor-bearing rats. Jpn J Pharmacol 18 245-
254. 
Kawase, A.; Tsunokuni, Y. & Iwaki, M. (2007a). Effects of alterations in CAR on bilirubin 
detoxification in mouse collagen-induced arthritis. Drug Metab Dispos 35 256-261. 
Kawase, A.; Yoshida, I.; Tsunokuni, Y. & Iwaki, M. (2007b). Decreased PXR and CAR inhibit 
transporter and CYP mRNA Levels in the liver and intestine of mice with collagen-
induced arthritis. Xenobiotica 37 366-374. 
Ke, S.; Rabson, A. B.; Germino, J. F.; Gallo, M. A. & Tian, Y. (2001). Mechanism of 
suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha 
and lipopolysaccharide. J Biol Chem 276 39638-39644. 
Kikuchi, R.; McCown, M.; Olson, P.; Tateno, C.; Morikawa, Y.; Katoh, Y.; Bourdet, D. L.; 
Monshouwer, M. & Fretland, A. J. (2010). Effect of hepatitis C virus infection on the 
mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric 
mice with humanized liver. Drug Metab Dispos 38 1954-1961. 
Kim, S. J.; Kang, H. S.; Jung, S. Y.; Min, S. Y.; Lee, S.; Kim, S. W.; Kwon, Y.; Lee, K. S.; Shin, K. 
H. & Ro, J. (2010). Methylation patterns of genes coding for drug-metabolizing 
enzymes in tamoxifen-resistant breast cancer tissues. J Mol Med (Berl) 88 1123-1131. 
Kim, S. K.; Abdelmegeed, M. A. & Novak, R. F. (2006). Identification of the insulin signaling 
cascade in the regulation of alpha-class glutathione S-transferase expression in 
primary cultured rat hepatocytes. J Pharmacol Exp Ther 316 1255-1261. 
Kim, S. K. & Novak, R. F. (2007). The role of intracellular signaling in insulin-mediated 
regulation of drug metabolizing enzyme gene and protein expression. Pharmacol 
Ther 113 88-120. 
Kim, Y. C.; Lee, A. K.; Lee, J. H.; Lee, I.; Lee, D. C.; Kim, S. H.; Kim, S. G. & Lee, M. G. 
(2005a). Pharmacokinetics of theophylline in diabetes mellitus rats: induction of 
CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26 114-
123. 
Kim, Y. C.; Lee, J. H.; Kim, S. H. & Lee, M. G. (2005b). Effect of CYP3A1(23) induction on 
clarithromycin pharmacokinetics in rats with diabetes mellitus. Antimicrob Agents 
Chemother 49 2528-2532. 
Kinloch, R. D.; Lee, C. M.; van Rooijen, N. & Morgan, E. T. (2011). Selective role for tumor 
necrosis factor-alpha, but not interleukin-1 or Kupffer cells, in down-regulation of 
CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal 
pathogen. Biochem Pharmacol 82 312-321. 
Kivisto, K. T.; Niemi, M.; Schaeffeler, E.; Pitkala, K.; Tilvis, R.; Fromm, M. F.; Schwab, M.; 
Lang, F.; Eichelbaum, M. & Strandberg, T. (2005). CYP3A5 genotype is associated 
www.intechopen.com
 
Topics on Drug Metabolism 
 
130 
with diagnosis of hypertension in elderly patients: data from the DEBATE Study. 
Am J Pharmacogenomics 5 191-195. 
Klotz, U.; McHorse, T. S.; Wilkinson, G. R. & Schenker, S. (1974). The effect of cirrhosis on 
the disposition and elimination of meperidine in man. Clin Pharmacol Ther 16 667-
675. 
Kraemer, M. J.; Furukawa, C. T.; Koup, J. R.; Shapiro, G. G.; Pierson, W. E. & Bierman, C. W. 
(1982). Altered theophylline clearance during an influenza B outbreak. Pediatrics 69 
476-480. 
Kulmatycki, K. M.; Abouchehade, K.; Sattari, S. & Jamali, F. (2001). Drug-disease 
interactions: reduced beta-adrenergic and potassium channel antagonist activities 
of sotalol in the presence of acute and chronic inflammatory conditions in the rat. 
Br J Pharmacol 133 286-294. 
Laporte, J. D.; Moore, P. E.; Panettieri, R. A.; Moeller, W.; Heyder, J. & Shore, S. A. (1998). 
Prostanoids mediate IL-1beta-induced beta-adrenergic hyporesponsiveness in 
human airway smooth muscle cells. Am J Physiol 275 L491-501. 
Lazarou, J.; Pomeranz, B. H. & Corey, P. N. (1998). Incidence of adverse drug reactions in 
hospitalized patients: a meta-analysis of prospective studies. Jama 279 1200-1205. 
Le, H. T.; Boquet, M. P.; Clark, E. A.; Callahan, S. M. & Croyle, M. A. (2006). Renal 
pathophysiology after systemic administration of recombinant adenovirus: changes 
in renal cytochromes P450 based on vector dose. Hum Gene Ther 17 1095-1111. 
Le Vee, M.; Gripon, P.; Stieger, B. & Fardel, O. (2008). Down-regulation of organic anion 
transporter expression in human hepatocytes exposed to the proinflammatory 
cytokine interleukin 1beta. Drug Metab Dispos 36 217-222. 
Lee, B. L.; Wong, D.; Benowitz, N. L. & Sullam, P. M. (1993). Altered patterns of drug 
metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol 
Ther 53 529-535. 
Lee, G. & Piquette-Miller, M. (2003). Cytokines alter the expression and activity of the 
multidrug resistance transporters in human hepatoma cell lines; analysis using RT-
PCR and cDNA microarrays. J Pharm Sci 92 2152-2163. 
Lee, G. H.; Proenca, R.; Montez, J. M.; Carroll, K. M.; Darvishzadeh, J. G.; Lee, J. I. & 
Friedman, J. M. (1996). Abnormal splicing of the leptin receptor in diabetic mice. 
Nature 379 632-635. 
Leemans, J. C.; Vervoordeldonk, M. J.; Florquin, S.; van Kessel, K. P. & van der Poll, T. 
(2002). Differential role of interleukin-6 in lung inflammation induced by 
lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am J Respir Crit 
Care Med 165 1445-1450. 
Lickteig, A. J.; Fisher, C. D.; Augustine, L. M.; Aleksunes, L. M.; Besselsen, D. G.; Slitt, A. L.; 
Manautou, J. E. & Cherrington, N. J. (2007a). Efflux transporter expression and 
acetaminophen metabolite excretion are altered in rodent models of nonalcoholic 
fatty liver disease. Drug Metab Dispos 35 1970-1978. 
Lickteig, A. J.; Fisher, C. D.; Augustine, L. M. & Cherrington, N. J. (2007b). Genes of the 
antioxidant response undergo upregulation in a rodent model of nonalcoholic 
steatohepatitis. J Biochem Mol Toxicol 21 216-220. 
Lind, D. S.; Hochwald, S. N.; Malaty, J.; Rekkas, S.; Hebig, P.; Mishra, G.; Moldawer, L. L.; 
Copeland, E. M., 3rd & Mackay, S. (2001). Nuclear factor-kappa B is upregulated in 
colorectal cancer. Surgery 130 363-369. 
www.intechopen.com
 
Altered Drug Metabolism and Transport in Pathophysiological Conditions 
 
131 
Lucas, D.; Farez, C.; Bardou, L. G.; Vaisse, J.; Attali, J. R. & Valensi, P. (1998). Cytochrome 
P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone 
hydroxylation. Fundam Clin Pharmacol 12 553-558. 
Maddox, J. F.; Amuzie, C. J.; Li, M.; Newport, S. W.; Sparkenbaugh, E.; Cuff, C. F.; Pestka, J. 
J.; Cantor, G. H.; Roth, R. A. & Ganey, P. E. (2010). Bacterial- and viral-induced 
inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol 
Environ Health A 73 58-73. 
Mannering, G. J. & Deloria, L. B. (1986). The pharmacology and toxicology of the interferons: 
an overview. Annu Rev Pharmacol Toxicol 26 455-515. 
Martin, G. S.; Mannino, D. M.; Eaton, S. & Moss, M. (2003). The epidemiology of sepsis in 
the United States from 1979 through 2000. N Engl J Med 348 1546-1554. 
Mayo, P. R.; Skeith, K.; Russell, A. S. & Jamali, F. (2000). Decreased dromotropic response to 
verapamil despite pronounced increased drug concentration in rheumatoid 
arthritis. Br J Clin Pharmacol 50 605-613. 
McHorse, T. S.; Klotz, U.; Wilkinson, G. & Schenker, S. (1974). Impaired elimination of 
meperidine in patients with liver disease. Trans Assoc Am Physicians 87 281-287. 
Meyer, U. A. (1996). Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 24 
449-459. 
Milosevic, N.; Schawalder, H. & Maier, P. (1999). Kupffer cell-mediated differential down-
regulation of cytochrome P450 metabolism in rat hepatocytes. Eur J Pharmacol 368 
75-87. 
Mizuno, N.; Niwa, T.; Yotsumoto, Y. & Sugiyama, Y. (2003). Impact of drug transporter 
studies on drug discovery and development. Pharmacol Rev 55 425-461. 
Mizuno, N. & Sugiyama, Y. (2002). Drug transporters: their role and importance in the 
selection and development of new drugs. Drug Metab Pharmacokinet 17 93-108. 
Modric, S.; Webb, A. I. & Derendorf, H. (1998). Pharmacokinetics and pharmacodynamics of 
tilmicosin in sheep and cattle. J Vet Pharmacol Ther 21 444-452. 
Monshouwer, M.; Witkamp, R. F.; Nijmeijer, S. M.; Pijpers, A.; Verheijden, J. H. & Van Miert, 
A. S. (1995). Selective effects of a bacterial infection (Actinobacillus 
pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, 
and indocyanine green in the pig. Xenobiotica 25 491-499. 
Monshouwer, M.; Witkamp, R. F.; Nujmeijer, S. M.; Van Amsterdam, J. G. & Van Miert, A. S. 
(1996). Suppression of cytochrome P450- and UDP glucuronosyl transferase-
dependent enzyme activities by proinflammatory cytokines and possible role of 
nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 137 237-
244. 
Mor, A.; Abramson, S. B. & Pillinger, M. H. (2005). The fibroblast-like synovial cell in 
rheumatoid arthritis: a key player in inflammation and joint destruction. Clin 
Immunol 115 118-128. 
Morris, S. M., Jr. & Billiar, T. R. (1994). New insights into the regulation of inducible nitric 
oxide synthesis. Am J Physiol 266 E829-839. 
Muntane-Relat, J.; Ourlin, J. C.; Domergue, J. & Maurel, P. (1995). Differential effects of 
cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human 
hepatocytes in primary culture. Hepatology 22 1143-1153. 
Naylor, M. S.; Stamp, G. W.; Foulkes, W. D.; Eccles, D. & Balkwill, F. R. (1993). Tumor 
necrosis factor and its receptors in human ovarian cancer. Potential role in disease 
progression. J Clin Invest 91 2194-2206. 
www.intechopen.com
 
Topics on Drug Metabolism 
 
132 
Nebert, D. W. & Russell, D. W. (2002). Clinical importance of the cytochromes P450. Lancet 
360 1155-1162. 
O'Neill, L. A. & Bowie, A. G. (2007). The family of five: TIR-domain-containing adaptors in 
Toll-like receptor signalling. Nat Rev Immunol 7 353-364. 
O'Shea, D.; Davis, S. N.; Kim, R. B. & Wilkinson, G. R. (1994). Effect of fasting and obesity in 
humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 
activity. Clin Pharmacol Ther 56 359-367. 
Park, J. H.; Lee, W. I.; Yoon, W. H.; Park, Y. D.; Lee, J. S. & Lee, M. G. (1998). 
Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous 
and oral administration to rats with alloxan-induced diabetes mellitus. Biopharm 
Drug Dispos 19 357-364. 
Park, J. M.; Moon, C. H. & Lee, M. G. (1996). Pharmacokinetic changes of methotrexate after 
intravenous administration to streptozotocin-induced diabetes mellitus rats. Res 
Commun Mol Pathol Pharmacol 93 343-352. 
Pascussi, J. M.; Dvorak, Z.; Gerbal-Chaloin, S.; Assenat, E.; Maurel, P. & Vilarem, M. J. 
(2003). Pathophysiological factors affecting CAR gene expression. Drug Metab Rev 
35 255-268. 
Petrovic, V.; Teng, S. & Piquette-Miller, M. (2007). Regulation of drug transporters during 
infection and inflammation. Mol Interv 7 99-111. 
Petrovic, V. & Piquette-Miller, M. (2010). Impact of polyinosinic/polycytidylic acid on 
placental and hepatobiliary drug transporters in pregnant rats. Drug Metab Dispos 
38 1760-1766. 
Philippe, L.; Gegout-Pottie, P.; Guingamp, C.; Bordji, K.; Terlain, B.; Netter, P. & Gillet, P. 
(1997). Relations between functional, inflammatory, and degenerative parameters 
during adjuvant arthritis in rats. Am J Physiol 273 R1550-1556. 
Pinder, M.; Bellomo, R. & Lipman, J. (2002). Pharmacological principles of antibiotic 
prescription in the critically ill. Anaesth Intensive Care 30 134-144. 
Piquette-Miller, M. & Jamali, F. (1992). Effect of adjuvant arthritis on the disposition of 
acebutolol enantiomers in rats. Agents Actions 37 290-296. 
Piquette-Miller, M. & Jamali, F. (1993). Selective effect of adjuvant arthritis on the 
disposition of propranolol enantiomers in rats detected using a stereospecific 
HPLC assay. Pharm Res 10 294-299. 
Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A. K.; Walley, T. J.; Farrar, K.; Park, 
B. K. & Breckenridge, A. M. (2004). Adverse drug reactions as cause of admission to 
hospital: prospective analysis of 18 820 patients. Bmj 329 15-19. 
Prescott, L. F.; Adjepon-Yamoah, K. K. & Talbot, R. G. (1976). Impaired Lignocaine 
metabolism in patients with myocardial infarction and cardiac failure. Br Med J 1 
939-941. 
Projean, D.; Dautrey, S.; Vu, H. K.; Groblewski, T.; Brazier, J. L. & Ducharme, J. (2005). 
Selective downregulation of hepatic cytochrome P450 expression and activity in a 
rat model of inflammatory pain. Pharm Res 22 62-70. 
Regazzi, M.; Maserati, R.; Villani, P.; Cusato, M.; Zucchi, P.; Briganti, E.; Roda, R.; Sacchelli, 
L.; Gatti, F.; Delle Foglie, P.; Nardini, G.; Fabris, P.; Mori, F.; Castelli, P. & Testa, L. 
(2005). Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human 
immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected 
subjects. Antimicrob Agents Chemother 49 643-649. 
www.intechopen.com
 
Altered Drug Metabolism and Transport in Pathophysiological Conditions 
 
133 
Renton, K. W. (1981). Depression of hepatic cytochrome P-450-dependent mixed function 
oxidases during infection with encephalomyocarditis virus. Biochem Pharmacol 30 
2333-2336. 
Reynaert, H.; Geerts, A. & Henrion, J. (2005). Review article: the treatment of non-alcoholic 
steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther 22 897-905. 
Richardson, T. A. & Morgan, E. T. (2005). Hepatic cytochrome P450 gene regulation during 
endotoxin-induced inflammation in nuclear receptor knockout mice. J Pharmacol 
Exp Ther 314 703-709. 
Robinson, L. J.; Roberts, W. K.; Ling, T. T.; Lamming, D.; Sternberg, S. S. & Roepe, P. D. 
(1997). Human MDR 1 protein overexpression delays the apoptotic cascade in 
Chinese hamster ovary fibroblasts. Biochemistry 36 11169-11178. 
Ronaldson, P. T. & Bendayan, R. (2006). HIV-1 viral envelope glycoprotein gp120 triggers an 
inflammatory response in cultured rat astrocytes and regulates the functional 
expression of P-glycoprotein. Mol Pharmacol 70 1087-1098. 
Rosso, R.; Dolfini, E. & Donelli, M. G. (1968). Prolonged effect of pentobarbital in tumor 
bearing rats. Eur J Cancer 4 133-135. 
Rosso, R.; Donelli, M. G.; Franchi, G. & Garattini, S. (1971). Impairement of drug metabolism 
in tumor-bearing animals. Eur J Cancer 7 565-577. 
Sakuma, T.; Honma, R.; Maguchi, S.; Tamaki, H. & Nemoto, N. (2001). Different expression 
of hepatic and renal cytochrome P450s between the streptozotocin-induced diabetic 
mouse and rat. Xenobiotica 31 223-237. 
Satoh, M.; Nakamura, M.; Saitoh, H.; Satoh, H.; Akatsu, T.; Iwasaka, J.; Masuda, T. & 
Hiramori, K. (2002). Aldosterone synthase (CYP11B2) expression and myocardial 
fibrosis in the failing human heart. Clin Sci (Lond) 102 381-386. 
Sattari, S.; Dryden, W. F.; Eliot, L. A. & Jamali, F. (2003). Despite increased plasma 
concentration, inflammation reduces potency of calcium channel antagonists due to 
lower binding to the rat heart. Br J Pharmacol 139 945-954. 
Schoene, B.; Fleischmann, R. A.; Remmer, H. & von Oldershausen, H. F. (1972). 
Determination of drug metabolizing enzymes in needle biopsies of human liver. 
Eur J Clin Pharmacol 4 65-73. 
Schrieber, S. J., Wen, Z., Vourvahis, M., Smith, P. C., Fried, M. W., Kashuba, A. D., Hawke, 
R. L. (2008). The pharmacokinetics of silymarin is altered in patients with hepatitis 
C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-
3/7 activity. Drug Metab Dispos 36 1909-1916. 
Scott, M. J.; Liu, S.; Shapiro, R. A.; Vodovotz, Y. & Billiar, T. R. (2009). Endotoxin uptake in 
mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine 
signaling-1-dependent mechanism. Hepatology 49 1695-1708. 
Sekino, K.; Kubota, T.; Okada, Y.; Yamada, Y.; Yamamoto, K.; Horiuchi, R.; Kimura, K. & 
Iga, T. (2003). Effect of the single CYP2C9*3 allele on pharmacokinetics and 
pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 59 
589-592. 
Sewer, M. B.; Koop, D. R. & Morgan, E. T. (1996). Endotoxemia in rats is associated with 
induction of the P4504A subfamily and suppression of several other forms of 
cytochrome P450. Drug Metab Dispos 24 401-407. 
Sewer, M. B. & Morgan, E. T. (1997). Nitric oxide-independent suppression of P450 2C11 
expression by interleukin-1beta and endotoxin in primary rat hepatocytes. Biochem 
Pharmacol 54 729-737. 
www.intechopen.com
 
Topics on Drug Metabolism 
 
134 
Sharma, R.; Kacevska, M.; London, R.; Clarke, S. J.; Liddle, C. & Robertson, G. (2008). 
Downregulation of drug transport and metabolism in mice bearing extra-hepatic 
malignancies. Br J Cancer 98 91-97. 
Shedlofsky, S. I.; Israel, B. C.; McClain, C. J.; Hill, D. B. & Blouin, R. A. (1994). Endotoxin 
administration to humans inhibits hepatic cytochrome P450-mediated drug 
metabolism. J Clin Invest 94 2209-2214. 
Shen, G. & Kong, A. N. (2009). Nrf2 plays an important role in coordinated regulation of 
Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm Drug 
Dispos 30 345-355. 
Shibata, N.; Shimakawa, H.; Minouchi, T. & Yamaji, A. (1993). Pharmacokinetics of 
cyclosporin A after intravenous administration to rats in various disease states. Biol 
Pharm Bull 16 1130-1135. 
Shimamoto, Y.; Kitamura, H.; Hoshi, H.; Kazusaka, A.; Funae, Y.; Imaoka, S.; Saito, M. & 
Fujita, S. (1998). Differential alterations in levels of hepatic microsomal cytochrome 
P450 isozymes following intracerebroventricular injection of bacterial 
lipopolysaccharide in rats. Arch Toxicol 72 492-498. 
Shimojo, N.; Ishizaki, T.; Imaoka, S.; Funae, Y.; Fujii, S. & Okuda, K. (1993). Changes in 
amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic 
and renal microsomes of rats with streptozocin-induced diabetes. Biochem 
Pharmacol 46 621-627. 
Shore, S. A.; Laporte, J.; Hall, I. P.; Hardy, E. & Panettieri, R. A., Jr. (1997). Effect of IL-1 beta 
on responses of cultured human airway smooth muscle cells to bronchodilator 
agonists. Am J Respir Cell Mol Biol 16 702-712. 
Singh, G. & Renton, K. W. (1981). Interferon-mediated depression of cytochrome P-450-
dependent drug biotransformation. Mol Pharmacol 20 681-684. 
Sonne, J.; Dossing, M.; Loft, S. & Andreasen, P. B. (1985). Antipyrine clearance in 
pneumonia. Clin Pharmacol Ther 37 701-704. 
Sukhai, M.; Yong, A.; Kalitsky, J. & Piquette-Miller, M. (2000). Inflammation and interleukin-
6 mediate reductions in the hepatic expression and transcription of the mdr1a and 
mdr1b Genes. Mol Cell Biol Res Commun 4 248-256. 
Synold, T. W.; Dussault, I. & Forman, B. M. (2001). The orphan nuclear receptor SXR 
coordinately regulates drug metabolism and efflux. Nat Med 7 584-590. 
Takeuchi, O.; Hoshino, K.; Kawai, T.; Sanjo, H.; Takada, H.; Ogawa, T.; Takeda, K. & Akira, 
S. (1999). Differential roles of TLR2 and TLR4 in recognition of gram-negative and 
gram-positive bacterial cell wall components. Immunity 11 443-451. 
Tan, F. L.; Moravec, C. S.; Li, J.; Apperson-Hansen, C.; McCarthy, P. M.; Young, J. B. & Bond, 
M. (2002). The gene expression fingerprint of human heart failure. Proc Natl Acad 
Sci U S A 99 11387-11392. 
Tantituvanont, A.; Yimprasert, W.; Werawatganone, P. & Nilubol, D. (2009). 
Pharmacokinetics of ceftiofur hydrochloride in pigs infected with porcine 
reproductive and respiratory syndrome virus. J Antimicrob Chemother 63 369-373. 
Teng, S. & Piquette-Miller, M. (2005). The involvement of the pregnane X receptor in hepatic 
gene regulation during inflammation in mice. J Pharmacol Exp Ther 312 841-848. 
Tett, S.; Moore, S. & Ray, J. (1995). Pharmacokinetics and bioavailability of fluconazole in 
two groups of males with human immunodeficiency virus (HIV) infection 
compared with those in a group of males without HIV infection. Antimicrob Agents 
Chemother 39 1835-1841. 
www.intechopen.com
 
Altered Drug Metabolism and Transport in Pathophysiological Conditions 
 
135 
Thomson, P. D.; Rowland, M. & Melmon, K. L. (1971). The influence of heart failure, liver 
disease, and renal failure on the disposition of lidocaine in man. Am Heart J 82 417-
421. 
Thum, T. & Borlak, J. (2002). Testosterone, cytochrome P450, and cardiac hypertrophy. Faseb 
J 16 1537-1549. 
Thummel, K. E. & Schenkman, J. B. (1990). Effects of testosterone and growth hormone 
treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 
37 119-129. 
Tirona, R. G.; Lee, W.; Leake, B. F.; Lan, L. B.; Cline, C. B.; Lamba, V.; Parviz, F.; Duncan, S. 
A.; Inoue, Y.; Gonzalez, F. J.; Schuetz, E. G. & Kim, R. B. (2003). The orphan nuclear 
receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of 
CYP3A4. Nat Med 9 220-224. 
Uno, S.; Kawase, A.; Tsuji, A.; Tanino, T. & Iwaki, M. (2007). Decreased intestinal CYP3A 
and P-glycoprotein activities in rats with adjuvant arthritis. Drug Metab 
Pharmacokinet 22 313-321. 
van Waarde, W. M.; Verkade, H. J.; Wolters, H.; Havinga, R.; Baller, J.; Bloks, V.; Muller, M.; 
Sauer, P. J. & Kuipers, F. (2002). Differential effects of streptozotocin-induced diabetes 
on expression of hepatic ABC-transporters in rats. Gastroenterology 122 1842-1852. 
Varin, F.; Ducharme, J.; Theoret, Y.; Besner, J. G.; Bevan, D. R. & Donati, F. (1990). Influence 
of extreme obesity on the body disposition and neuromuscular blocking effect of 
atracurium. Clin Pharmacol Ther 48 18-25. 
Vee, M. L.; Lecureur, V.; Stieger, B. & Fardel, O. (2009). Regulation of drug transporter 
expression in human hepatocytes exposed to the proinflammatory cytokines tumor 
necrosis factor-alpha or interleukin-6. Drug Metab Dispos 37 685-693. 
Veronese, L.; Rautaureau, J.; Sadler, B. M.; Gillotin, C.; Petite, J. P.; Pillegand, B.; Delvaux, 
M.; Masliah, C.; Fosse, S.; Lou, Y. & Stein, D. S. (2000). Single-dose 
pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease 
inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents 
Chemother 44 821-826. 
Warren, G. W.; Poloyac, S. M.; Gary, D. S.; Mattson, M. P. & Blouin, R. A. (1999). Hepatic 
cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) 
knockout mice after endotoxin administration. J Pharmacol Exp Ther 288 945-950. 
Warren, G. W.; van Ess, P. J.; Watson, A. M.; Mattson, M. P. & Blouin, R. A. (2001). 
Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after 
induction of the acute-phase response. J Interferon Cytokine Res 21 821-826. 
Watkins, J. B., 3rd & Sherman, S. E. (1992). Long-term diabetes alters the hepatobiliary clearance 
of acetaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 260 1337-1343. 
Wellen, K. E. & Hotamisligil, G. S. (2005). Inflammation, stress, and diabetes. J Clin Invest 
115 1111-1119. 
Weltman, M. D.; Farrell, G. C.; Hall, P.; Ingelman-Sundberg, M. & Liddle, C. (1998). Hepatic 
cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. 
Hepatology 27 128-133. 
Wichterman, K. A.; Baue, A. E. & Chaudry, I. H. (1980). Sepsis and septic shock--a review of 
laboratory models and a proposal. J Surg Res 29 189-201. 
Wild, S.; Roglic, G.; Green, A.; Sicree, R. & King, H. (2004). Global prevalence of diabetes: 
estimates for the year 2000 and projections for 2030. Diabetes Care 27 1047-1053. 
www.intechopen.com
 
Topics on Drug Metabolism 
 
136 
Wilkinson, G. R. (1997). The effects of diet, aging and disease-states on presystemic 
elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev 27 129-159. 
Williams, J. A. & Phillips, D. H. (2000). Mammary expression of xenobiotic metabolizing 
enzymes and their potential role in breast cancer. Cancer Res 60 4667-4677. 
Williams, M. L.; Bhargava, P.; Cherrouk, I.; Marshall, J. L.; Flockhart, D. A. & Wainer, I. W. 
(2000). A discordance of the cytochrome P450 2C19 genotype and phenotype in 
patients with advanced cancer. Br J Clin Pharmacol 49 485-488. 
Williams, R. O.; Feldmann, M. & Maini, R. N. (1992). Anti-tumor necrosis factor ameliorates 
joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89 9784-
9788. 
Wonganan, P.; Zamboni, W. C.; Strychor, S.; Dekker, J. D. & Croyle, M. A. (2009). Drug-virus 
interaction: effect of administration of recombinant adenoviruses on the 
pharmacokinetics of docetaxel in a rat model. Cancer Gene Ther 16 405-414. 
Woodcroft, K. J.; Hafner, M. S. & Novak, R. F. (2002). Insulin signaling in the transcriptional 
and posttranscriptional regulation of CYP2E1 expression. Hepatology 35 263-273. 
Wyles, D. L. & Gerber, J. G. (2005). Antiretroviral drug pharmacokinetics in hepatitis with 
hepatic dysfunction. Clin Infect Dis 40 174-181. 
Xie, W. (2008). Nuclear receptors in drug metabolism, John Wiley & Sons, Inc. ISBN: 978-0-470-
08679-7, Hoboken, New Jersey.  
Xiong, H.; Yoshinari, K.; Brouwer, K. L. & Negishi, M. (2002). Role of constitutive 
androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by 
phenobarbital. Drug Metab Dispos 30 918-923. 
Yoh, K.; Ishii, G.; Yokose, T.; Minegishi, Y.; Tsuta, K.; Goto, K.; Nishiwaki, Y.; Kodama, T.; 
Suga, M. & Ochiai, A. (2004). Breast cancer resistance protein impacts clinical 
outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. 
Clin Cancer Res 10 1691-1697. 
Yoshinari, K.; Takagi, S.; Sugatani, J. & Miwa, M. (2006a). Changes in the expression of 
cytochromes P450 and nuclear receptors in the liver of genetically diabetic db/db 
mice. Biol Pharm Bull 29 1634-1638. 
Yoshinari, K.; Takagi, S.; Yoshimasa, T.; Sugatani, J. & Miwa, M. (2006b). Hepatic CYP3A 
expression is attenuated in obese mice fed a high-fat diet. Pharm Res 23 1188-1200. 
Young, L. C.; Campling, B. G.; Voskoglou-Nomikos, T.; Cole, S. P.; Deeley, R. G. & Gerlach, 
J. H. (1999). Expression of multidrug resistance protein-related genes in lung 
cancer: correlation with drug response. Clin Cancer Res 5 673-680. 
Young, M. J.; Clyne, C. D.; Cole, T. J. & Funder, J. W. (2001). Cardiac steroidogenesis in the 
normal and failing heart. J Clin Endocrinol Metab 86 5121-5126. 
Yu, L. & Chen, S. (2008). Toll-like receptors expressed in tumor cells: targets for therapy. 
Cancer Immunol Immunother 57 1271-1278. 
Yu, R.; Lei, W.; Mandlekar, S.; Weber, M. J.; Der, C. J.; Wu, J. & Kong, A. N. (1999). Role of a 
mitogen-activated protein kinase pathway in the induction of phase II detoxifying 
enzymes by chemicals. J Biol Chem 274 27545-27552. 
Zhou, J.; Liu, M.; Aneja, R.; Chandra, R.; Lage, H. & Joshi, H. C. (2006). Reversal of P-
glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-
terminal kinase. Cancer Res 66 445-452. 
Zordoky, B. N. & El-Kadi, A. O. (2009). Role of NF-kappaB in the regulation of cytochrome 
P450 enzymes. Curr Drug Metab 10 164-178. 
www.intechopen.com
Topics on Drug Metabolism
Edited by Dr. James Paxton
ISBN 978-953-51-0099-7
Hard cover, 294 pages
Publisher InTech
Published online 22, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In order to avoid late-stage drug failure due to factors such as undesirable metabolic instability, toxic
metabolites, drug-drug interactions, and polymorphic metabolism, an enormous amount of effort has been
expended by both the pharmaceutical industry and academia towards developing more powerful techniques
and screening assays to identify the metabolic profiles and enzymes involved in drug metabolism. This book
presents some in-depth reviews of selected topics in drug metabolism. Among the key topics covered are: the
interplay between drug transport and metabolism in oral bioavailability; the influence of genetic and epigenetic
factors on drug metabolism; impact of disease on transport and metabolism; and the use of novel microdosing
techniques and novel LC/MS and genomic technologies to predict the metabolic parameters and profiles of
potential new drug candidates.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Adarsh Gandhi and Romi Ghose (2012). Altered Drug Metabolism and Transport in Pathophysiological
Conditions, Topics on Drug Metabolism, Dr. James Paxton (Ed.), ISBN: 978-953-51-0099-7, InTech, Available
from: http://www.intechopen.com/books/topics-on-drug-metabolism/altered-drug-metabolism-and-transport-in-
pathophysiological-conditions
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
